Despite clear evidence that activation of PI3K/Akt/mTOR pathway contributes to RCC development and progression, inhibition of mTOR and/or PI3K did not provide effective and long-lasting anticancer benefits (Alzahrani, 2019). The gene discussed is MTOR; the disease is renal cell carcinoma.